ATRX.US Adhera Therapeutics Inc
- Market cap
- USD 722.00
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is ATRX.US undervalued?
Graham numberThe Graham number of Adhera Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Adhera Therapeutics Inc fundamental analysis
No fundamental analysis for Adhera Therapeutics Inc yet.
Adhera Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Adhera Therapeutics Inc
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.
Full company profileAdhera Therapeutics Inc financial statements
Adhera Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 500K | 680K | 0.00 | 0.00 | 76.2K | 252K | 132K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 500K | 680K | -49.2K | -451K | -383K | -157K | 27.0K | - | - | - |
| Operating Income | -3.52M | -3.99M | -758K | -6.09M | -15.8M | -11.3M | -2.04M | -674K | -1.62M | -1.28M |
| EBITDA | -5.47M | -3.99M | -709K | -5.64M | -16.3M | -11.2M | -1.59M | -276K | -1.62M | - |
| Net Income | -6.48M | 3.34M | -837K | -6.22M | -16.8M | -12.0M | -3.77M | -6.35M | 2.35M | -4.49M |
| EPS | -53 | 20 | -3.53 | -13 | -31 | -22 | -6.93 | -9.77 | 1.02 | - |
| Balance Sheet | ||||||||||
| Total Assets | 9.22M | 7.60M | 6.19M | 6.18M | 5.14M | 420K | 1.00K | 196K | 79.0K | - |
| Total Liabilities | 13.6M | 7.33M | 2.97M | 5.74M | 2.21M | 10.3M | 14.8M | 25.3M | 22.3M | - |
| Shareholders' Equity | -4.37M | 263K | 3.22M | 448K | 2.93M | -9.89M | -14.8M | -25.1M | -22.2M | - |
| Cash & Short-term Investments | 1.82M | 710K | 105K | 106K | 3.92M | 50.0K | 1.00K | 76.0K | 32.0K | - |
| Total Debt | 1.62M | - | 686K | 1.91M | - | 5.33M | 6.32M | 6.66M | 8.59M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -4.78M | -2.17M | -522K | -1.26M | -9.61M | -8.74M | -588K | -665K | -1.42M | -714K |
| Capital Expenditure | 0.00 | 45.0K | 74.0K | 375K | 74.4K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -4.78M | -2.21M | -522K | -1.64M | -9.69M | -8.74M | -588K | -665K | -1.42M | -714K |
| Ratios | ||||||||||
| ROE | - | 1,268.8% | -26.0% | -1,387.4% | -572.5% | - | - | - | - | - |
| ROA | -70.3% | 43.9% | -13.5% | -100.6% | -325.9% | -2,851.9% | -376,600.0% | -3,240.3% | 2,977.2% | - |
| Net Profit Margin | -1,295.4% | 490.7% | - | - | -21,992.2% | -4,753.2% | -2,853.0% | - | - | - |
| Debt to Equity | - | - | 0.21x | 4.25x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Adhera Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2023 | - | - | - |
| 2022 | USD 620K | 0.27 | 26.4% |
| 2021 | USD 2.05M | 3.16 | - |
| 2020 | USD 1.54M | 2.83 | - |
| 2019 | USD 1.51M | 2.78 | - |
| 2018 | USD 1.06M | 1.96 | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
| 2015 | USD 690K | 4.20 | 20.7% |
| 2014 | USD 6.00M | 49 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Oct 6, 2022.
Who owns Adhera Therapeutics Inc
Ownership data of Adhera Therapeutics Inc is not available yet.
Adhera Therapeutics Inc company profile
- Company name
- Adhera Therapeutics Inc
- Ticker
- ATRX.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 8000 Innovation Parkway, Baton Rouge, LA, United States, 70820
- Phone
- 919 518 3748
- Website
- adherathera.com
About Adhera Therapeutics Inc
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.
Adhera Therapeutics Inc management
1- Mr. Andrew Albert Kucharchuk M.B.A.Vice Chairman, COO & Chief Business Officer · born 1981